Table 14: Impact of CXL on Best Corrected Visual Acuity at 12-Months*.
| Author, Year | Patients | Improvement BCVA ≥ 1Snellen line | No Change BCVA | Loss BCVA |
|---|---|---|---|---|
| Koller T, 2009 (55) | 105 | NR | NR | 2.9% (95% CI 0.6% - 8.5%) ≥ 2 Snellen line |
| Agrawal V, 2009 (49) | 37 | 20 (54%) | 10 (28%) Lines Not defined |
NR |
| Arbelaez M, 2009 (50) | 20 | 12 (60%) | 8 (40%) Lines Not defined |
− |
| Doors M, 2009 (52) | 20 | 10 (50%) | 5 (25%) Lines Not defined |
NR |
| El-Raggal T, 2009 (53) | 15 | 4 (27%) | NR | 1 (7%) 1 line |
| Raiskup-Wolf F, 2008 (6) | 142 | 75 (53%) | 29 (20%) Lines Not defined |
NR |
| Hersch P, 2011 (47) | 49 | 22 (45%) | 23 (46%) Within 1 Snellen line |
4 (10%) 1 Snellen line |
| Wollensak G, 2003 (7) | 22 | 11 (50%) | 9 (41%) Within 1 Snellen line |
2 (9%) ≥ 1 Snellen line |
| Range 27% | 27% − 60% | 20% − 46% | 2.9% − 10% |
*
BCVA indicates best corrected visual acuity; CI, confidence interval; NR, not reported; P, patients